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Our previous studies have shown that genistein can enhance the insulin-like growth factor (IGF)-1 receptor signalling pathway via an oestrogen
receptor (ER) in human breast cancer MCF-7 cells. The present study aims to investigate how genistein regulates IGF-1 receptor expression in
human MCF-7 cells. Genistein at 1mM stimulated the growth of MCF-7 cells and this effect could be completely blocked by the IGF-1 receptor
antagonist JB-1, suggesting that IGF-1 receptor is essential for mediating the proliferative effects of genistein in MCF-7 cells. Genistein increased
IGF-1 receptor promoter activity. This effect could be completely abolished by co-treatment of MCF-7 cells with ICI 182,780 (1026 M). Genistein
increased IGF-1 receptor gene expression and this effect could be completely blocked by the IGF-1 receptor antagonist JB-1. Co-treatment of
MCF-7 cells with cycloheximide (5mg/ml) completely blocked the induction of IGF-1 receptor protein and mRNA expression by genistein.
The results indicated that the induction of IGF-1 receptor promoter activity by genistein required the action of ER while the stimulatory actions
of genistein on IGF-1 receptor expression required the activity of the IGF-1 receptor and de novo protein synthesis. These data provide evidence to
support the hypothesis that the inductive effects of genistein on IGF-1 receptor expression require the cross-talk between IGF-1 receptor and the
ER-dependent pathways.
Genistein: Oestrogen: Insulin-like growth factor 1 receptor: Oestrogen receptor: Human breast cancer
Genistein, a natural isoflavone phyto-oestrogen present in
soyabeans, has a chemical structure similar to that of steroidal
oestrogens, and its ability to behave as an oestrogen in various
tissues has been widely described1,2. Genistein has been found
to have significant oestrogenic properties in both in vitro and
in vivo studies. Physiological concentrations (1029–1026 M)
of genistein stimulate the growth of oestrogen receptor
(ER)-positive breast cancer cells3,4. In ovariectomised athymic
mice implantedwithMCF-7 cells, both genistein and soya protein
stimulate tumour growth in a dose-dependent fashion5,6.
Many studies have revealed the mechanism of the oestro-
genic effects of genistein. Genistein binds to the ER and acti-
vates a number of oestrogen-responsive genes in vitro7,8,
although its binding affinity is several-fold weaker than that
of 17b-oestradiol (E2). Studies clearly demonstrate the pre-
sence of independent but interacting mitogenic pathways in
the ER-positive breast cancer cells, including the ER pathway
and the insulin-like growth factor (IGF)-1 receptor pathway9.
Oestrogen-stimulated mitogenesis in the ER-positive human
breast cancer cells could be mediated both by the ER signal-
ling pathway and the enhancement of the IGF-1 signalling
pathway. E2 can induce the expression of several members
of the IGF family in human breast cancer cells, including
IGF-1 receptor, IGF-2 receptor, IGF binding proteins, insulin
receptor substrate 1 and insulin receptor substrate 2. The up
regulation of these proteins by E2 provides the potential mech-
anisms for its autocrine and paracrine control of breast cancer
cell mitogenesis10,11. Our previous studies clearly indicated
that, apart from the classical ER signalling pathway, the pro-
liferative effects of genistein on the ER-positive human breast
cancer MCF-7 cells are also related to the IGF-1 receptor sig-
nalling pathway12. Genistein mimics the action of E2 and
causes the induction of IGF-1 receptor and insulin receptor
substrate 1 expression in MCF-7 cells in a time-dependent
manner. In the present study, our aim was to investigate
the detailed mechanism by which genistein activates IGF-1
receptor transcription and expression in human breast cancer
MCF-7 cells.
Materials and methods
Culture of human breast cancer cell line (MCF-7)
MCF-7 cells (ATCC no. HTB-22; ATCC, Manassas, VA,
USA) were routinely cultured in Dulbecco’s modified
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Eagle’s medium (DMEM) supplemented with 5% fetal bovine
serum (FBS), penicillin (100 international units/ml) and strep-
tomycin (100mg/ml) (Invitrogen, Carlsbad, CA, USA) at 378C
in a humidified atmosphere of 95% air and 5% CO2. Cells
were transferred to phenol red-free DMEM supplemented
with 1% charcoal-stripped FBS, penicillin (100 units/ml)
and streptomycin (100mg/ml) by standard methods of trypsini-
sation, plated in six-well dishes for 5 d and allowed to replicate
to 80% confluence. Then cells were treated either with genis-
tein (1026 M) or E2 (10
28
M) (Sigma, St Louis, MO, USA) for
48 h. The medium and test compounds were replenished at
24 h. For anti-oestrogen, IGF-1 receptor antagonist JB-1 or
cycloheximide (CHX) treatment, MCF-7 cells were exposed
to genistein or E2 in the presence or absence of ICI 182,780
(1026 M; Tocris, Bristol, UK), JB-1 (1mg/ml; Bachem,
Bubendorf, Switzerland) or CHX (1026 M; Sigma, St Louis,
MO, USA) for 48 h.
Cell proliferation assays
For the growth study, MCF-7 cells were seeded in ninety-six-
well plates (3 £ 103 cells/well) in phenol red-free DMEM sup-
plemented with 1% charcoal-stripped FBS for 4 d and then
treated with genistein (1026 M) or E2 (10
28
M) with or without
ICI 182,780 or JB-1 for 48 h. As an indirect measure of
growth, the 3-[4, 5-dimethylthiazol 2-yl] 2, 5-diphenyltetra-
zolium bromide (MTT) assay was used as described pre-
viously13. Briefly, the medium was removed and replaced
with 100ml tetrazolium (MTT, 5mg/ml; Sigma) in PBS.
The plates were incubated for 4 h at 378C, followed by the
addition of 100ml of lysis buffer (0·04M-HCl in propan-2-ol).
The multi-well plates were shaken for 1 h and the signals
were detected by a microplate reader using a wavelength of
595 nm.
Insulin-like growth factor 1 receptor promoter luciferase
assay
The effect of genistein on IGF-1 receptor promoter activity
was studied by transient transfection assays using a genomic
DNA fragment extending from nucleotides 22350 to þ640
(nucleotide corresponds to the transcription site of rat IGF-1
receptor gene) or promoterless luciferase construct that was
kindly provided by Dr Derek LeRoith (Diabetes Branch,
Bethesda, MD, USA). MCF-7 cells were seeded in twelve-
well plates for 1 d in DMEM medium supplemented
with 5% FBS. Cells were then transferred to phenol red-
free DMEM supplemented with 1% charcoal-stripped FBS
for another 2 d. MCF-7 cells were transfected with 0·8mg
of reporter plasmid along with 0·4mg of the control reporter
plasmids pRL-TK using the Lipofectamine 2000 reagent
according to the manufacturer’s instructions (Invitrogen).
At 5 h after transfection, cells were treated with genistein
or E2 in the presence or absence of 10
26
M-ICI 182,780
for another 24 h and then harvested. Luciferase activity
encoded by experimental and internal control plasmid
was measured sequentially with the use of a TD-20/20
Luminometer (Turner Design, Sunnyvale, CA, USA) and
the Dual-Luciferase Reporter reagents according to the
supplier’s recommendation (Promega, Madison, WI, USA).
The IGF-1 receptor promoter activity was expressed as
firefly luciferase values normalised by pRL-TK renilla
luciferase values.
Semi-quantitative reverse transcriptase-polymerase chain
reaction for insulin-like growth factor 1 receptor expression
Total RNA was isolated from cells by using Trizol reagent
according to the standard protocol. Total RNA (2mg) was
used to generate cDNA in each sample using SuperScript II
RT with oligo(dT) 12-18 primers (Invitrogen). The evaluation
of pS2 and IGF-1 receptor expression was performed by semi-
quantitative RT-PCR as previously described12. PCR amplifi-
cation was performed on a GeneAmp 9600 PCR system
(Perkin Elmer, Foster City, CA, USA). Cycle-response
curves for each PCR product had been determined to derive
the optimal cycle for each gene candidate. The cycles that
were chosen would ensure that the PCR product upon normal-
isation with the expression of housekeeping gene glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) between samples
could be compared semi-quantitatively. For IGF-1 receptor
and GAPDH, the primers used were 50-ACTATGCCGGTGT-
CTGTGTG-30 (IGF-1 receptor forward) and 50-TGCAAGTT-
CTGGTTGTCGAG-30 (IGF-1 receptor reverse), and 50-ACC-
ACAGTCCATGCCTACAC-30 (GAPDH forward) and 50-
TTCACCACCCTGTTGCTGTA-30 (GAPDH reverse) to
yield products of 522 and 422 bp, with thirty and twenty
PCR cycles, respectively. The PCR products were analysed
using agarose gel electrophoresis. Optical densities of
ethidium bromide-stained DNA bands were quantified using
a luminal imager (Lumi-Imager; Roche Molecular Biochemi-
cals, Mannheim, Germany).
Immunoblotting
For Western blotting, protein was isolated from cells using
Trizol reagent according to the standard protocol. Protein con-
centrations were analysed by the method of Bradford (Bio-
Rad, Hercules, CA, USA)14. Equal amount of proteins
(5mg) were separated by SDS-PAGE on 10% reducing gels
at a constant voltage (150V) for 1 h as previously described15,
and transblotted onto polyvinylidene difluoride (PVDF) mem-
branes (Immobilin-P; Millipore Corp., Beverly, MA, USA).
Immunodetection was performed after blocking non-specific
binding sites on the membrane with 5% skimmed milk. The
blots were probed with polyclonal rabbit anti-human IGF-1
receptor b (1:2000; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA) as the primary antibody, followed by incu-
bation with the goat anti-rabbit antibody conjugated with
horseradish peroxidase (1:2000; Santa Cruz Biotechnology,
Inc.) as the secondary antibody for 1 h. The antigen–antibody
complexes were then detected with enhanced chemilumines-
cence reagent16 and visualised by the Lumi-Imager
using Lumi Analyst version 3.10 software (Roche Molecular
Biochemicals).
Statistical analysis
Data are reported as mean values with their standard errors.
Significance of differences between group means was deter-
mined by one-way ANOVA.
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Results
Role of insulin-like growth factor 1 receptor in mediating the
proliferative effects of genistein in human breast cancer
(MCF-7) cells
Genistein and E2 have proliferative effects on human breast
cancer (MCF-7) cells. Their proliferative effects could be
completely abolished by co-incubation of MCF-7 cells with
IGF-1 receptor antagonist JB-1 (Fig. 1). As JB-1 is a selective
competitive antagonist of IGF-1 receptor autophosphorylation,
the inhibition of the action of E2 and genistein by JB-1
suggests that IGF-1 receptor plays a pivotal role in mediating
the proliferative effects of both E2 and genistein in human
breast cancer (MCF-7) cells.
Effect of genistein on insulin-like growth factor 1 receptor
promoter activity
Our previous study clearly shows that IGF-1 receptor
expression is increased upon treatment with a physiological
concentration of genistein in a time-dependent manner12. To
determine if the increase in IGF-1 receptor expression by gen-
istein was mediated by the up regulation of IGF-1 receptor
promoter activities, a transient transfection assay was per-
formed. MCF-7 cells were transiently transfected with IGF-1
receptor luciferase promoter p(2350/þ640)Luc or promoter-
less luciferase construct for 5 h, followed by treatment with
genistein (1026 M) or E2 (10
28
M) for another 24 h. As
shown in Fig. 2, genistein and E2 significantly increased the
IGF-1 receptor promoter luciferase activity and their induction
could be abolished by co-treatment with the anti-oestrogen
ICI 182,780. There was no luciferase activity detected in the
cells that were transfected with promoterless luciferase con-
struct (data not shown). These results suggest that genistein
and E2 could directly up regulate IGF-1 receptor gene
expression by their stimulatory actions on IGF-1 receptor
promoter activities, and it appears that these effects are also
ER-dependent.
Effect of JB-1 on insulin-like growth factor 1 receptor gene
expression induced by genistein
To determine if functional IGF-1 receptor was required for
genistein up regulation of IGF-1 receptor gene expression,
MCF-7 cells treated with either genistein or E2 were co-incu-
bated with or without the IGF-1 receptor antagonist JB-1.
The up regulation of IGF-1 receptor gene expression induced
by genistein was completely abolished by JB-1 (Fig. 3),
indicating that the stimulatory effect of genistein on IGF-1
receptor expression not only required the ER-dependent
pathway but also involved the activity of functional IGF-1
receptor. The action of genistein on IGF-1 receptor was
similar to those of E2, as JB-1 could also abolish the up
regulation of IGF-1 receptor gene expression induced by E2
(Fig. 4).
Up regulation of insulin-like growth factor 1 receptor
expression by genistein requires oestrogen receptor and de
novo protein synthesis
Our previous results clearly show that genistein and E2
could increase the gene and protein expression of IGF-1
receptor and these effects could be completely blocked by
the anti-oestrogen ICI 182,78012. To further investigate the
potential mechanism involved in the up regulation of IGF-
1 receptor expression by genistein, MCF-7 cells treated
with either genistein or E2 were co-incubated with or with-
out CHX (5mg/ml), a de novo protein synthesis inhibitor.
The expression of IGF-1 receptor induced by E2 was com-
pletely blocked by CHX at both protein and mRNA level
(Figs. 4 (A) and (B)), indicating that de novo protein syn-
thesis is required for the action of E2. Similar to the
action of E2, the up regulation of IGF-1 receptor protein
and mRNA by genistein could be blocked by CHX treat-
ment (Figs. 4 (A) and (B)) and thus requires de novo
protein synthesis.
Fig. 1. Effect of genistein on cell proliferation in human breast cancer
(MCF-7) cells. MCF-7 cells were cultured and treated with either 1026 M-gen-
istein (G) or 1028 M-17b-oestradiol (E) in the presence or absence of JB-1
(1mg/ml) for 48 h, and then cell number was determined by the 3-[4,
5-dimethylthiazol 2-yl] 2, 5-diphenyltetrazolium bromide assay. Values are
means for four independent experiments, with standard errors represented
by vertical bars. Mean value was significantly different from that for control
(C): **P,0·01, ***P,0·001.
Fig. 2. Insulin-like growth factor (IGF)-1 receptor promoter luciferase
assay. MCF-7 cells were cultured and treated with 1026M-genistein (G) or
1028M-17b-oestradiol (E) in the presence and absence of 1026 M-ICI 182,780
(I) for 24h. Activities of luciferases encoded by experimental and internal control
plasmid were measured sequentially with the Dual-Luciferase Reporter assay
reagents. The IGF-1 receptor promoter firefly luciferase activities were
normalised with pRL-TK renilla luciferase values. The IGF-1 receptor promoter
luciferase activity of control (C) was defined as 100%. Values are means for
three independent experiments, with standard errors represented by vertical
bars. **Mean value was significantly different from that for control (P,0·01).
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Discussion
Genistein, a planar molecule with an aromatic A ring, has a
chemical structure similar to that of steroidal oestrogens,
and its ability to behave as an oestrogen in various tissues
has been widely described. Our previous studies have shown
that genistein has biphasic effects on the growth of the ER-
positive human breast cancer (MCF-7) cells, in which high
concentration (. 1025 M) inhibits17 while low concentration
(1026 M) stimulates breast cancer cell proliferation12. Our pre-
vious study clearly demonstrates that genistein has oestrogen-
like activities and exerts its action via the activation of the
IGF-1 receptor signalling pathway in human breast cancer
MCF-7 cells12. In the present study, we provide further evi-
dence that the IGF-1 receptor antagonist JB-1 can completely
block the stimulatory effect of genistein on MCF-7 cells. Geni-
stein can activate the transcription of IGF-1 receptor via ER.
The stimulation of IGF-1 receptor expression by genistein
appears to be related to the cross-talk of the ER pathway
and the IGF-1 receptor pathway as well as de novo protein
synthesis.
The IGF-1 receptor is a receptor–tyrosine kinase that plays a
critical role in signalling, cell survival and proliferation. The
IGF-1 receptor is necessary for normal breast biology, but
recent clinical and experimental data strongly suggest that the
same receptors are involved in the development of breast
cancer18. The IGF-1 receptor is over-expressed in the ER-posi-
tive breast cancer cells compared with its levels in normal epi-
thelial cells. Studies clearly demonstrate the presence of
independent but interacting mitogenic pathways in the ER-posi-
tive breast cancer cells, including the ER pathway and the IGF-1
receptor pathway9. In the present study, we used JB-1, a peptide
analogue of IGF-1 that is involved in binding to the IGF-1
receptor. It is a potent, highly selective, competitive antagonist
of IGF-1 receptor autophosphorylation and cellular prolifer-
ation. The present results clearly demonstrate the proliferative
actions and the stimulatory effects on IGF-1 receptor induced
by genistein and oestrogen could be completely blocked by
co-treatmentwith JB-1. Thesefindings suggest that IGF-1 recep-
tor activation is necessary for the stimulatory effects of genistein
and oestrogen in human breast cancer cells.
The IGF-1 and ER systems are engaged in a powerful func-
tional cross-talk in human tissues. E2 and IGF-1 act together to
stimulate proliferation in normal mammary epithelium and
increase the risk of breast cancer19. IGF-1 may activate ER in
the absence of estrogens in different cell types11,20. IGF-1 can
modulate oestrogen action by acting via the tyrosine kinase of
the IGF-1 receptor. Ligands for IGF-1 receptor can regulate
Fig. 3. Effect of JB-1 on insulin-like growth factor (IGF)-1 receptor gene
expression induced by genistein in human breast cancer (MCF-7) cells.
MCF-7 cells were cultured and treated with either 1026 M-genistein (G) or
1028 M-17b-oestradiol (E) in the presence or absence of JB-1 (1mg/ml) for
48 h. Total RNA was isolated and IGF-1 receptor and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) mRNA expressions were subjected to semi-
quantitative RT-PCR analysis. The mRNA expression level was expressed
as a ratio to the expression of GAPDH. Values are means for three indepen-
dent experiments, with standard errors represented by vertical bars. Mean
value was significantly different from that for control (C): *P,0·05, **P,0·01.
Fig. 4. Effect of cycloheximide (CHX) on the regulation of insulin-like growth
factor (IGF)-1 receptor expression by genistein or 17b-oestradiol. MCF-7
cells were cultured and treated with 1026 M-genistein (G) or 1028 M-17b-oes-
tradiol (E) in the presence or absence of 1026 M-CHX for 48 h. (A) IGF-1
receptor and b-actin protein expression. (B) Semi-quantitative RT-PCR anal-
ysis of IGF-1 receptor and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA expression. Values are means for three independent exper-
iments, with standard errors represented by vertical bars. Mean values with
unlike letters were significantly different (P,0·05).
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ER gene expression and ER-mediated transcription in an
oestrogen-independentmanner21. In turn, oestrogen can activate
the IGF-1 receptor signalling pathway at different levels. At
the cell surface, oestrogen induces ER and IGF-1 receptor
association, probably through an adapter protein and
increases IGF-1 receptor phosphorylation22. Accumulating
evidence indicates that the oestrogen-responsive region in the
IGF-1 receptor promoter was mapped to a guanine-cytosine
(GC)-rich sequence located between nucleotides 240 and
2188 in the 50 flanking region. A recent study reported that
the effect of E2 on IGF-1 receptor expression was at least
partly mediated through the activation of the Sp1 transcription
factor in breast cancer cells23.
Genistein can mimic oestrogen to stimulate ER-positive cell
proliferation. Our previous study clearly showed that genistein
mimicked E2 in stimulating the IGF-1 receptor signalling
pathway and the effect was ER-dependent. The present
study clearly further demonstrates the involvement of the
cross-talk between ER and the IGF-1 receptor-dependent
signalling pathway in mediating the actions of genistein in
MCF-7 cells. Genistein not only increases the protein and
mRNA expression of the IGF-1 receptor but also increases
IGF-1 receptor promoter activity. These effects could be com-
pletely abolished by co-treatment of MCF-7 cells with ICI
180,782. These results clearly suggest that an increase in
IGF-1 receptor transcription at least in part accounts for the
induction of IGF-1 receptor expression by genistein and the
effect is ER-dependent.
The present study also further determines the potential
mechanism involved in the up regulation of IGF-1 receptor
expression by genistein. CHX, a de novo protein synthesis
inhibitor, can completely abolish the up regulation of IGF-1
receptor expression at both protein and mRNA level. In the
case of protein expression, it is clearly shown that blocking
new protein synthesis can prevent the translation of IGF-1
receptor mRNA into protein. As for the case of IGF-1 receptor
mRNA expression, these results suggest that some labile pro-
teins (with short half-lives in vivo) could be essential for the
genistein activation of IGF-1 receptor transcription. Inhibition
of new protein synthesis will prevent these labile proteins
from being synthesised. Examples of these proteins could be
proteins involved in the transcription machinery (coactivator
and co-repressor).
In summary, the present data provide the first evidence
that genistein activates the transcription of IGF-1 receptor
gene expression. The stimulation of IGF-1 receptor expression
by genistein appears to require the association of ER and IGF-
1 receptor as well as de novo protein synthesis. Most impor-
tantly, the present study provides the mechanistic basis to
understand how genistein mimics oestrogen by activating
ER–IGF-1 receptor cross-talk to stimulate human breast
cancer cell growth. Thus, pre- and post-menopausal women
who are at risk of developing ER-positive breast cancer
should be cautioned when considering using genistein as
an alternative approach to manage menopause-related
syndromes.
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